Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cerdulatinib (PRT2070) 是一种选择性 Tyk2抑制剂,IC50为 0.5 nM。它是 JAK 和 SYK 的双抑制剂,抑制JAK1、2、3 和SYK 的IC50分别为12、6、8 和 32。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 289 | 现货 | ||
5 mg | ¥ 536 | 现货 | ||
10 mg | ¥ 715 | 现货 | ||
25 mg | ¥ 1,180 | 现货 | ||
50 mg | ¥ 1,790 | 现货 | ||
100 mg | ¥ 2,730 | 现货 | ||
200 mg | ¥ 3,830 | 现货 | ||
500 mg | ¥ 5,950 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 588 | 现货 |
产品描述 | Cerdulatinib (PRT2070) is an novel oral dual Syk/JAK inhibitor. |
靶点活性 | TYK2:0.5 nM |
体外活性 | Cerdulatinib exhibits an inhibitory effect on 60 CLL with IC50 ranging from 0.37 to 10.02 μM. Cerdulatinib induces apoptosis in CLL in association with MCL-1 down-regulation and PARP cleavage. Cerdulatinib (2 μM) is able to overcome the support of the microenvironment and induces cell death of CLL. Cerdulatinib (250-500 nM) blocks proliferation of ibrutinib-sensitive and ibrutinib-resistant primary CLL cells. Cerdulatinib also blocks proliferation of both ibrutinib-sensitive and ibrutinib-resistant primary CLL cells as well as BTKC481S-transfected cell lines, and blocks BCR and JAK-STAT signaling pathways. Furthermore, inhibition of SYK and JAK by cerdulatinib translates to downstream inhibition of AKT and ERK. Cerdulatinib inhibits the activity of NF-kB pathway[1]. PRT062070 reduces the ability of stimulated B cells to upregulate cell-surface expression of the early activation marker CD69 (IC50=0.11 μM). PRT062070 exhibits differential potency against cytokine JAK/STAT signaling pathways. PRT062070 (1 or 3 μM) induces apoptosis in BCR-signaling competent NHL cell lines[2]. Cerdulatinib demonstrates inhibitory activity against both ABC and GCB subtypes of DLBCL cells. Cerdulatinib also induces apoptosis in both GCB and ABC subtypes of DLBCL cell lines via caspase 3 and PARP cleavage. And cerdulatinib blocks cell cycle in both ABC and GCB subtypes of DLBCL via inhibition of RB phosphorylation and down-regulation of cyclin E. Cerdulatinib induces cell cycle arrest and apoptosis under the condition of BCR stimulation in all DLBCL cell lines. Besides, cerdulatinib blocks JAK/STAT and BCR signaling in both ABC and GCB DLBCL cell lines. Cerdulatinib induces cell death in primary human DLBCL samples[3]. Cerdulatinib inhibits BCR-induced signals in a dose-dependent manner and most strongly between 0.3 to 1 μM. and particularly in IGHV-unmutated samples with greater BCR signaling capacity and response to IL4, or samples expressing higher levels of sIgM, CD49d+, or ZAP70+. Cerdulatinib overcomes anti-IgM, IL4/CD40L, or NLC-mediated protection by preventing upregulation of MCL-1 and BCL-XL; however, BCL-2 expression is unaffected. Moreover, cerdulatinib synergizes with venetoclax in vitro to induce greater apoptosis than either drug alone in samples treated with IL4/CD40L[4]. |
体内活性 | PRT062070 (0.5 mg/kg) causes a nonstatistically significant trend toward reduced ankle inflammation, whereas significant reductions in inflammation are achieved with the 1.5, 3, and 5 mg/kg doses. Besides, PRT062070 also affects anticollagen antibody formation. PRT062070 (15 mg/kg) suppresses upregulation of splenic B-cell surface CD80/86 and CD69, and inhibits BCR signaling and activation in the spleen after oral dosing in mice[2]. |
细胞实验 | Cerdulatinib is dissolved in DMSO. TMD8 cells are transfected with constructs of WT BTK or BTKC481S mutants using kit V, Program U-13 on Amaxa Nucleofector. After transfection, the cells are co-cultured with NKTert cells in a 24-well plate for 24 hrs for recovery. Ibrutinib, cerdulatinib and vehicle (DMSO) are then added into the transfected TMD8 cells and cellular viability is determined with MuseTM Count & Viability kit using Muse Cell Analyzer. The cell survival is determined by flow cytometry using the Annexin V/7-AAD Apoptosis Detection Kit I on freshly isolated CLL cells. |
别名 | PRT2070, 赛度替尼, PRT062070 |
分子量 | 445.54 |
分子式 | C20H27N7O3S |
CAS No. | 1198300-79-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: ~20 mg/mL (44.9 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2445 mL | 11.2223 mL | 22.4447 mL | 56.1117 mL |
5 mM | 0.4489 mL | 2.2445 mL | 4.4889 mL | 11.2223 mL | |
10 mM | 0.2244 mL | 1.1222 mL | 2.2445 mL | 5.6112 mL | |
20 mM | 0.1122 mL | 0.5611 mL | 1.1222 mL | 2.8056 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Cerdulatinib 1198300-79-6 Angiogenesis Chromatin/Epigenetic JAK/STAT signaling Stem Cells Tyrosine Kinase/Adaptors Tyrosine Kinases JAK Syk PRT2070 Spleen tyrosine kinase inhibit PRT 2070 PRT 062070 Inhibitor 赛度替尼 Janus kinase PRT062070 PRT-062070 PRT-2070 inhibitor